Navigation Links
The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services

Toronto, Canada (PRWEB) January 14, 2014

In recent years, growing suspicion about the pharmaceutical industry and its motives and methods in product development and promotion has led to unprecedented levels of public mistrust of the industry. This mistrust, fueled by concerns about the insidious impact of commercialization of research, has been further fed by reports of spectacular fines to the world’s biggest pharmas for illegal marketing activities, allegations of industry suppression of negative clinical trial results, and fears of “influence peddling” through physician payments of various sorts.

The Physician Payments Sunshine Act (“The Sunshine Act”) is the US Congress’s response to these concerns. The Physician Payments Sunshine Act (Sunshine Act) requires manufacturers of drugs, medical devices and biologicals that participate in U.S. federal health care programs to report certain payments and items of value given to physicians and teaching hospitals.

Manufacturers are required to collect and track payment, transfer and ownership information beginning Aug. 1, 2013. Manufacturers will submit the reports to the Centers for Medicare & Medicaid Services (CMS) on an annual basis. In addition, manufacturers and group purchasing organizations (GPOs) must report certain ownership interests held by physicians and their immediate family members. The majority of the information contained in the reports will be available on a public, searchable website.

These new reporting requirements have imposed a considerable burden on all concerned, including IRBs, sponsors, CROs, clinical investigators, and certainly government. Will this added regulatory burden prove effective in promoting more ethical research with improved outcomes for patients and society?

For more information about this event or to register, visit The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation.

About IRB Services
Founded in 1993, IRB Services is an independent organization dedicated to protecting the rights and safety of human research subjects. As one of the largest central institutional review boards in North America, IRB Services is an experienced, service-driven organization dedicated to excellence in human research participant protection and committed to providing industry leading efficient customer-oriented services. IRB Services provides ethical review of clinical trials and behavioral science research and operates ethics committees in Boca Raton, Florida; Montréal, Québec; and Toronto, Ontario; which review a wide range of both industry and publicly funded human subject research across multiple disciplines, including Food and Drug Administration, US Department of Health and Human Services, and Health Canada regulated research. IRB Services has received full accreditation from the Association for the Accreditation of Human Research Protection Programs. For more information please visit

About Xtalks
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks, visit

Michelle Tran, Marketing Manager
(416) 977-6555 ext 224

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Clinverse, Inc. Introduces ClinSpend to Meet Challenges of Sunshine Act Reporting Requirements
2. Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks
3. Online Courses Address Latest Healthcare Compliance Regulations
4. CfPIE Announces Advisory Board to Support Continued Life Sciences Training Alignment with Industry Regulations
5. Study dusts sugar coating off little-known regulation in cells
6. Swiss, EMA, US Pharmacopoeia and World Health Organization Authorities to Provide an Update on Cool Chain Regulations
7. Gordon Hunter's New Science Book Perfect for the Everyday Environmentalist
8. Bayer CropScience Reveals Insights into U.S. Potato Industry’s Top Needs for 2014 During Potato Expo
9. Isolation Sciences’ CAP Device Found to Reduce Energy Use by More Than 80 Percent
10. Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome
11. Science Magazine: Cancer Immunotherapy is the Medical Breakthrough of 2013; The CBCD Highlights the Link between Immunotherapy and Microcompetition
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):